Recent patents on biotechnology最新文献

{"title":"Meet the Editorial Board Member","authors":"Younes Ghasemi","doi":"10.2174/187220831801231012235532","DOIUrl":"https://doi.org/10.2174/187220831801231012235532","url":null,"abstract":"","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140092338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of Camelus dromedaries Immune Single Domain Antibodies Library for Development of Schistosoma mansoni Specific Nanobodies Using Phage Display Strategy","authors":"Hadeer Adel El-Kalamawy, Mohamed Awwad, Tarek Diab, Hend Okasha, Amal M. Abdel-Kareim, M. Marawan, Salma A. Shoulah, E. El-Dabaa","doi":"10.2174/0118722083275669231227063413","DOIUrl":"https://doi.org/10.2174/0118722083275669231227063413","url":null,"abstract":"\u0000\u0000Schistosoma mansoni poses a considerable global public health\u0000challenge. In Egypt, approximately 60% of the inhabitants in the Northern and Eastern\u0000areas of the Nile Delta are affected by this parasite, whereas the Southern region experiences\u0000a significantly lower infection rate of 6%.\u0000\u0000\u0000\u0000Schistosoma (S.) mansoni infect 60% of the population in the Northern and Eastern parts of the Nile Delta and only 6% in the Southern part. Therefore, seeking for cost effective, sensitive and specific diagnostic tool for rapid detection of S. mansoni is necessary. Variable domains of camelid heavy-chain antibodies (VHHs) which are known as nanobodies (Nb) are approximately 15 kDa in size with high affinity to their antigens. Phage display technology was used in construction of Nbs library based on the camelid VHH framework for selection of S. mansoni specific Nbs\u0000\u0000\u0000\u0000Construction of an immune phage display Nbs library based on the VHH framework\u0000for selecting S. mansoni-specific Nbs for seeking cost-effective, sensitive, and specific\u0000diagnostic tools for rapidly detecting Schistosoma mansoni.\u0000\u0000\u0000\u0000Camel was immunized using soluble adult worm antigens (SAWP) for the production\u0000of Variable domains of heavy chains of camelid heavy-chain only antibodies\u0000(VHHs), which are known as nanobodies (Nb). The PBMCs repertoires VHH sequences\u0000library have been constructed with a high percentage of insertion and right orientation using\u0000pADL-23c phagmid and M13 phage followed by three rounds of bio-panning against\u0000SAWP using phage display technique. Evaluations using polyclonal phage ELISA and\u0000other techniques have been carried out to reveal the successful enrichment of anti-SAWP\u0000Nbs (VHH) clones. Evaluation of the diagnostic potentiality of these Nbs was carried out\u0000using ELISA on human serum samples confirmed for S. mansoni infection. Receiver Operator\u0000of Characteristics (ROC) curve analysis was used for discrimination between S.\u0000mansoni infection and both negative controls and the Fasciola hepatica group.\u0000\u0000\u0000\u0000Using monoclonal ELISA, Nbs of 22 clones out of 24 selected clones showed\u0000binding affinity to SAWP. The cutoff values of the produced anti-S. mansoni Nbs was >\u00000.19, leading to 80% sensitivity, 95% specificity, and 90% accuracy. Sequence analysis of\u0000three of these Nbs with high binding affinities showed diversity in their targets, considering\u0000their CDR3 aa sequences.\u0000\u0000\u0000\u0000Using monoclonal ELISA, Nbs of 22 clones out of 24 selected clones showed binding affinity to SAWP. Sequence analysis of three of these Nbs with high binding affinities showed diversity in their targets considering their CDR3 aa sequences.\u0000\u0000\u0000\u0000This study successfully produced high diversity, anti-S.mansoni VHHs enriched\u0000phage library and the generated nanobodies have high diagnostic potential for S.\u0000mansoni infection in human patients.\u0000\u0000\u0000\u0000We had successfully constructed high diversity VHH immune library against S. mansoni SAWP which can be efficiently used to develop anti-S. mansoni Nbs for diagnosis.\u0000","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140485930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Edible Vaccines: A Patent-Driven Exploration of Immunization Technologies.","authors":"Sahil Kashyap, Shikha Kamboj, Rohit Kamboj, Kumar Guarve, Sweta Kamboj","doi":"10.2174/0118722083275041231219060829","DOIUrl":"https://doi.org/10.2174/0118722083275041231219060829","url":null,"abstract":"<p><p>Vaccines are biological preparations that improve immunity to particular diseases. Particularly for poor developing nations, edible vaccines show significant potential as a financially advantageous, simple to administer, straightforward to store, fail-safe, and socially and culturally acceptable vaccine delivery system. A vaccine incorporates the gene-encoding bacterial or viral disease-causing agent in plants without losing its immunogenic property. Potatoes, tomatoes, rice, soybeans, and bananas are the primary plants for edible vaccines. It activates the systemic and mucosal immunity responses against a foreign disease-causing organism. It offers exciting possibilities to reduce diseases like hepatitis B, rabies, HIV/AIDS (human immunodeficiency virus infection and acquired immune deficiency syndrome), etc. These vaccines provide many benefits, like being convenient to administer, efficiently storing, and readily acceptable drug delivery systems for patients of different age groups. So, an edible vaccine may be the most convenient vaccine to improve immunity. However, there are a lot of technical and regulatory challenges to overcome in the way of edible vaccine technology. Though all seem surmountable, various technical obstacles and regulatory and non-scientific challenges need to be overcome. Moreover, edible vaccine patents represent a cutting-edge area of biotechnology, where the integration of genetic material into edible substances holds great promise for revolutionizing vaccination methods. These patents aim to harness the potential of plants and other edibles to stimulate immune responses, offering a potential alternative to traditional injectable vaccines. This review states the technologies, host plants, current status, recent patents, the future of this new preventive modality, and different regulatory issues concerning edible vaccines.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139567388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicinal Plants in the Treatment of Respiratory Diseases and their Future Aspects.","authors":"Aliya Firdaus, Mohd Hadi Yunus, Syed Khalida Izhar, Uzma Afaq","doi":"10.2174/0118722083278561231212072408","DOIUrl":"https://doi.org/10.2174/0118722083278561231212072408","url":null,"abstract":"<p><p>The utilization of medicinal plants in the treatment of respiratory diseases has a rich history dating back centuries. This study delves into the diverse range of plant species known for their therapeutic properties, with a specific focus on their applications in respiratory health. Medicinal plants have played a crucial role as a source of ingredients for medications and the synthesis of drugs. Globally, over 35,000 plant species are employed for medicinal purposes, particularly in emerging countries where traditional medicine, predominantly plant-based pharmaceuticals, serves as a primary healthcare resource. This review highlights the significance of medicinal plants, such as aloe, ginger, turmeric, tulsi, and neem, in treating a wide array of common respiratory ailments. These plants contain bioactive compounds, including tannins, alkaloids, sugars, terpenoids, steroids, and flavonoids, which have diverse therapeutic applications. Some medicinal plants, notably Echinacea purpurea and Zingiber officinale, exhibit potential for adjuvant symptomatic therapy in respiratory conditions, such as chronic obstructive pulmonary disease (COPD), bronchitis, asthma, the common cold, cough, and whooping cough. The leaves of medicinal plants like Acacia torta, Ocimum sanctum, Mentha haplocalyx, Lactuca virosa, Convolvulus pluricaulis, and Acalypha indica are commonly used to address pneumonia, bronchitis, asthma, colds, and cough. This review aims to shed light on specific medicinal plants with therapeutic value, providing valuable insights for researchers in the field of herbal medicine. These plants hold the potential to serve as novel therapeutic agents in the treatment of respiratory diseases.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139562963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing a Secretory form of RTX-A as an Anticancer Toxin: An\u0000In Silico Approach","authors":"Mortaza Taheri‐Anganeh, Navid Nezafat, S. Gharibi, S. H. Khatami, Farzaneh Vahedi, Zahra Shabaninejad, Marzieh Asadi, A. Savardashtaki, A. Movahedpour, Hassan Ghasemi","doi":"10.2174/0118722083267796231210060150","DOIUrl":"https://doi.org/10.2174/0118722083267796231210060150","url":null,"abstract":"\u0000\u0000Cancer is a leading cause of death and a significant public health\u0000issue worldwide. Standard treatment methods such as chemotherapy, radiotherapy, and\u0000surgery are only sometimes effective. Therefore, new therapeutic approaches are needed\u0000for cancer treatment. Sea anemone actinoporins are pore-forming toxins (PFTs) with\u0000membranolytic activities. RTX-A is a type of PFT that interacts with membrane phospholipids, resulting in pore formation. The synthesis of recombinant proteins in a secretory\u0000form has several advantages, including protein solubility and easy purification. In this\u0000study, we aimed to discover suitable signal peptides for producing RTX-A in Bacillus\u0000subtilis in a secretory form.\u0000\u0000\u0000\u0000Signal peptides were selected from the Signal Peptide Web Server. The probability and secretion pathways of the selected signal peptides were evaluated using the\u0000SignalP server. ProtParam and Protein-sol were used to predict the physico-chemical\u0000properties and solubility. AlgPred was used to predict the allergenicity of RTX-A linked\u0000to suitable signal peptides. Non-allergenic, stable, and soluble signal peptides fused to\u0000proteins were chosen, and their secondary and tertiary structures were predicted using\u0000GOR IV and I-TASSER, respectively. The PROCHECK server performed the validation\u0000of 3D structures.\u0000\u0000\u0000\u0000According to bioinformatics analysis, the fusion forms of OSMY_ECOLI and\u0000MALE_ECOLI linked to RTX-A were identified as suitable signal peptides. The final\u0000proteins with signal peptides were stable, soluble, and non-allergenic for the human body.\u0000Moreover, they had appropriate secondary and tertiary structures.\u0000\u0000\u0000\u0000The signal above peptides appears ideal for rationalizing secretory and soluble RTX-A. Therefore, the signal peptides found in this study should be further investigated through experimental research.\u0000","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139446514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring <i>Trachyspermum ammi</i> and <i>Foeniculum vulgare</i> in Hydroponic System and Compare its Chemical Constituents with Soil-Based Method: A Prospective in Agriculture.","authors":"Shilpa Debnath, Alok Sharma","doi":"10.2174/1872208317666230601104843","DOIUrl":"10.2174/1872208317666230601104843","url":null,"abstract":"<p><strong>Background: </strong>The forthcoming problems will be of food, and soil due to environmental alteration, growing populations, pollution, and exhaustion of natural resources among other factors. Hydroponic farming has the capacity to alleviate the intimidation of these con-cerned issues in the agricultural system. Hydroponics is recommended as an alternative way to enhance product yield compared to conventional agriculture.</p><p><strong>Objective: </strong>The present study aimed to determine the different growth parameters and constituents of soil-grown and hydroponically grown <i>Trachyspermum ammi </i> and <i>Foeniculum vulgare</i> for the first time, which could be a patentable in future.</p><p><strong>Methods: </strong>In this study, extraction was carried out by maceration method using methanol as a solvent whereas, growth parameters were performed by the leaves number, plant height, and leaf area. Chlorophyll content was also performed in both sources. Further, a comparison of chemical constituents from different sources was analyzed by GC-MS.</p><p><strong>Results: </strong>The bioactive components in hydroponically grown <i>T. ammi</i> were found more as compared to soil-grown <i>T. ammi</i>. The GC-MS analysis revealed the presence of various compounds in the methanolic extract of plant materials.</p><p><strong>Conclusion: </strong>Hence, hydroponics could be an alternative in agriculture and this system is now accepted globally. This method provides diverse perspectives for farmers to harvest high-yield, better quality, and enhanced bioactive compounds.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44406029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nano Lipid Carriers as a Promising Drug Delivery Carrier for Neurodegenerative Disorders - An Overview of Recent Advances.","authors":"Vishal Kumar, Sreeja C Nair","doi":"10.2174/1872208317666230320164219","DOIUrl":"10.2174/1872208317666230320164219","url":null,"abstract":"<p><p>The last few decades have seen a rise in the number of deaths caused by neurological disorders. The blood-brain barrier (BBB), which is very complex and has multiple mechanisms, makes drug delivery to the brain challenging for many scientists. Lipid nanoparticles (LNPs) such as nanoemulsions, solid-lipid nanoparticles, liposomes, and nano lipid carriers (NLCs) exhibit enhanced bioavailability and flexibility among these nanocarriers. NLCs are found to be very effective. In the last few decades, they have been a center of attraction for controlled drug delivery. According to the current global status of specific neurological disorders, out of all LNPs, NLC significantly reduces the cross-permeability of drugs through the BBB due to their peculiar properties. They offer a host of advantages over other carriers because of their biocompatibility, safety, non-toxicity, non-irritating behavior, stability, high encapsulation efficiency, high drug loading, high drug targeting, control of drug release, and ease in manufacturing. The biocompatible lipid matrix is ideally suited as a drug carrier system due to the nano-size range. For certain neurological conditions such as Parkinsonism, Alzheimer's, Epilepsy, Multiple sclerosis, and Brain cancer, we examined recent advances in NLCs to improve brain targeting of bioactive with special attention to formulation aspects and pharmacokinetic characteristics. This article also provides a brief overview of a critical approach for brain targeting, <i>i.e.</i>, direct nose-to-brain drug delivery and some recent patents published on NLC\".</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46813496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Algal-derived Bioactive Compounds in Human Health.","authors":"Gyanendra Tripathi, Priyanka Dubey, Suhail Ahmad, Alvina Farooqui, Vishal Mishra","doi":"10.2174/1872208317666230623141740","DOIUrl":"10.2174/1872208317666230623141740","url":null,"abstract":"<p><p>Algae is emerging as a bioresource with high biological potential. Various algal strains have been used in traditional medicines and human diets worldwide. They are a rich source of bioactive compounds like ascorbic acid, riboflavin, pantothenate, biotin, folic acid, nicotinic acid, phycocyanins, gamma-linolenic acid (GLA), adrenic acid (ARA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), etc. Beta-carotene, astaxanthin, and phycobiliproteins are different classes of pigments that are found in algae. They possess antioxidant, anti-inflammatory and anticancer properties. The sulfur-coated polysaccharides in algae have been used as an anticancer, antibacterial, and antiviral agent. Scientists have exploited algal-derived bioactive compounds for developing lead molecules against several diseases. Due to the surge in research on bioactive molecules from algae, industries have started showing interest in patenting for the large-scale production of bioactive compounds having applications in sectors like pharmaceuticals, food, and beverage. In the food industry, algae are used as a thickening, gelling, and stabilizing agent. Due to their gelling and thickening characteristics, the most valuable algae products are macroalgal polysaccharides such as agar, alginates, and carrageenan. The high protein, lipid, and nutrient content in microalgae makes it a superfood for aquaculture. The present review aims at describing various non-energy-based applications of algae in pharmaceuticals, food and beverage, cosmetics, and nutraceuticals. This review attempts to analyze information on algal-derived drugs that have shown better potential and reached clinical trials.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9988634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review on Romiplostim Mechanism of Action and the Expressive Approach in <i>E. coli</i>.","authors":"Masoud Hashemzaei, Mohammad Bagher Ghoshoon, Mehrnaz Jamshidi, Fatemeh Moradbeygi, Ahmad Hashemzehi","doi":"10.2174/1872208317666230503094451","DOIUrl":"10.2174/1872208317666230503094451","url":null,"abstract":"<p><p>Immune thrombocytopenic purpura (ITP) is an autoimmune disorder determined by immune-mediated platelet demolition and reduction of platelet production. Romiplostim is a new thrombopoiesis motivating peptibody that binds and stimulates the human thrombopoietin receptor the patent of which was registered in 2008. It is used to treat thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Romiplostim is a 60 kDa peptibody designed to inhibit cross-reacting immune responses. It consists of four high-affinity TPO-receptor binding domains for the Mpl receptor and one human IgG1 Fc domain. <i>Escherichia coli</i> is a good host for the fabrication of recombinant proteins such as romiplostim. The expression of a gene intended in <i>E. coli</i> is dependent on many factors such as a protein's inherent ability to fold, mRNA's secondary structure, its solubility, its toxicity preferential codon use, and its need for post-translational modification (PTM). This review focuses on the structure, function, mechanism of action, and expressive approach to romiplostim in <i>E. coli</i>.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44001349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potentials of Stem Cell Therapy in Patients Infected with COVID- 19: A Systematic Review.","authors":"Zahra Tamis, Fatemeh Sadeghi, Aigin Heydari, Saima Shahzad Mirza, Mohammad Hossein Morowvat","doi":"10.2174/1872208317666230818092522","DOIUrl":"10.2174/1872208317666230818092522","url":null,"abstract":"<p><strong>Introduction: </strong>In the present study, we have examined different aspects and potentials of stem cells for the management of patients infected with COVID-19.</p><p><strong>Background: </strong>The novel coronavirus disease (COVID-19) has been reported in most of the countries and territories (>230) of the world with .686 million confirmed cases (as of Apr. 22, 2023). While the scientific community is working to develop vaccines and develop drugs against the COVID-19 pandemic, novel alternative therapies may reduce the mortality rate. Recently, the application of stem cells for critically ill COVID-19 patients in a small group of patients has been examined.</p><p><strong>Methods: </strong>We searched PubMed, Web of Science, and Google Scholar up to July 2022. Those studies that reviewed COVID-19 and cell therapy potentials were entered into the study. Moreover, some recently published patents were exploited and reviewed. Patentscope, USPTO, Espacenet, Free Patents Online, and Google Patents were used for patent searches.</p><p><strong>Results: </strong>Cell-based therapy as a modality of regenerative medicine is considered one of the most promising disciplines in the fields of modern science and medicine. Such an advanced technology offers endless possibilities for transformative and potentially curative treatments for some of the most life-threatening diseases. This therapeutic tool can be useful to reduce the rate of mortality. There have been several published patents for different stem cell therapy platforms in recent years.</p><p><strong>Conclusion: </strong>Stem cell therapy could be considered a safe and effective therapeutic strategy to reduce death cases in patients infected with COVID-19. Besides, stem cell therapy might increase the pulmonary functions in the patients, it suppresses the occurring inflammations and ameliorates the symptoms.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10078159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}